Mansur Shomali, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1194789370
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,000 of the $11,005 with a category attached, or 90.9%. Abbott accounts for 94.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $10,375 and has fallen 100.0% since, to $1 in 2025.
Across 20 payments — averaging $550.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Dexcom, Inc.$118
- Bayer$105
- Merck$69
- Boehringer Ingelheim$67
- Corcept Therapeutics$60
- plus $187 from 7 others
What the payments were for
- Consulting fees$3753%
- Speaking & faculty fees$10,00091%
- Food & beverage$6176%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $10,399 |
| Dexcom, Inc. | 1 | $118 |
| Bayer | 1 | $105 |
| Merck | 1 | $69 |
| Boehringer Ingelheim | 2 | $67 |
| Corcept Therapeutics | 2 | $60 |
| Novo Nordisk | 3 | $53 |
| Valeritas, Inc. | 2 | $43 |
| Novartis | 1 | $31 |
| Amgen | 1 | $27 |
| Shire North American Group Inc | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| BETA Bionics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre Pro$375
- DEXCOM G7 GSS (161)$118
- Kerendia$105
How this compares
$11,005 in reported general payments places this provider in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 222 | $363,167 |
| OzempicSemaglutide | 130 | $216,635 |
| JardianceEmpagliflozin | 110 | $152,468 |
| MounjaroTirzepatide | 63 | $109,355 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $37,026 |
| FarxigaDapagliflozin Propanediol | 24 | $31,454 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $20,454 |
| InvokanaCanagliflozin | 20 | $19,839 |
| KerendiaFinerenone | 17 | $19,631 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $16,295 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $11,990 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $9,203 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $4,902 |
| Novolog FlexpenInsulin Aspart | 25 | $4,249 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 41 | $3,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $53 | $216,635130 claims |
| Boehringer IngelheimJardiance | $67 | $152,468110 claims |
| BayerKerendia | $105 | $19,63117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Philip LevinBaltimore$489K
- Adrian DobsBaltimore$149K
- Todd BrownBaltimore$143K
- Roberto SalvatoriBaltimore$53K
- Nowreen HaqBaltimore$40K
- Asif MohamedBaltimore$31K
- Sherita GoldenBaltimore$27K
- Jean ParkBaltimore$13K
- Malek CheikhBaltimore$9K
- Paul SackBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.